Article Text

PDF
330 SAFETY AND EFFICACY OF RETREATING FOLLICULAR NON-HODGKIN'S LYMPHOMA WITH 90Y IBRITUMOMAB TIUXETAN (ZEVALIN).
  1. J. Shah1,
  2. J. Mueh2,
  3. J. Lister3,
  4. S. Jasthy3,
  5. M. Gregory4,
  6. C. Mckay5,
  7. R. Krumdieck6,
  8. A. Forero1
  1. 1University of Alabama at Birmingham, Birmingham, AL
  2. 2Kaiser Permanente, Honolulu, HI
  3. 3Western Pennsylvania Cancer Institute, Pittsburgh, PA
  4. 4Foundation for Cancer Research and Education, Phoenix, AZ
  5. 5Tennessee Oncology, Nashville, TN
  6. 6Lake Norman Hematology Oncology Specialists, Mooresville, NC

Abstract

Background There are no data regarding safety and efficacy of treating follicular non-Hodgkin's lymphoma (NHL) patients with a second course of Zevalin.

Methods Patients with follicular NHL who received two courses of Zevalin therapy were identified nationally, and data were retrospectively collected.

Results Ten patients (mean age 62.5 years, 48-91) were identified. Prior to the first Zevalin, all patients received chemotherapy (mean 2.4 courses, 1-5), 3 of 10 auto-PBSCT, and 4 of 10 external beam radiotherapy (ebRT). After the initial course of treatment, the mean time to nadir for the anemia was 7.9 weeks (4-13), neutropenia was 6.7 weeks (4-10), and thrombocytopenia was 5.2 weeks (4-8). One patient required growth factor support and transfusions; two had an incomplete recovery of platelet count at 23 and 30 weeks (76,000 and 126,000/μL). Hematologic toxicity and grades are in the table below. Prior to the second course of Zevalin two patients received ebRT, one received 131I tositumomab, and three received chemotherapy (1-5 regimens). The median time to the second Zevalin course was 613 days (183-1,300). After the second course of Zevalin, the mean time to nadir for the anemia was 8.2 wks (2-25); neutropenia was 6.7 weeks (4-10); and thrombocytopenia was 5.5 weeks (4-7). Four of 10 patients required growth factor support, 2 required transfusions, 3 had incomplete recovery of platelet count and early progression, and 2 had a maximum recovery of their platelet count at 29 and 40 weeks (143,000 and 144,000/μL). There were no infectious or bleeding complications with either course of Zevalin. No secondary myelodysplastic syndrome or acute leukemia was reported.

Conclusions Retreating patients with follicular NHL with a second course of Zevalin is tolerable, with substantial evidence of clinical efficacy.

TABLE 1

Toxicity and Efficacy with Zevalin Retreatment

Statistics from Altmetric.com

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.